How do you pay?

How to pay the least

Ask for the cash price

Ziextenzo

Ziextenzo is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

  1. Ask your pharmacy for Ziextenzo’s cash price, and one or two other pharmacies too.
  2. Ziextenzo’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameZiextenzo
Authorized genericpegfilgrastim-bmez
Regular genericpegfilgrastim-bmez
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Ziextenzo?
The original
–
–

Brand nameThe maker’s card

ZIEXTENZO Co-Pay Program (Sandoz One Source)

Savings card from Sandoz

No insuranceNeeds insuranceNo cash price listed.
Insurance $0 a dose

Sign up on ziextenzo.com 

From the maker’s offer on ziextenzo.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Ziextenzo itself, from the same company, sold without the brand name, and usually for less. For now Ziextenzo is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Ziextenzo is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

ZIEXTENZO is a leukocyte growth factor indicated to

  • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
  • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Limitations of Use

ZIEXTENZO is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Source: the FDA label for Ziextenzo (Sandoz Inc), May 14, 2026. Full label on DailyMed 

Good to know